ITGAX and neoplasm: Next, we quantified the proliferating bona fide cytotoxic CD3 (GZMB+), FOXP3+, CD11c+ immune cells, and tumor cells (Pan-CK+) in the stroma and tumor areas by staining for the proliferation marker Ki67 (Fig. 3E, F and Supplementary Fig. 2E).